0001104659-22-053615.txt : 20220429 0001104659-22-053615.hdr.sgml : 20220429 20220429162200 ACCESSION NUMBER: 0001104659-22-053615 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20220429 DATE AS OF CHANGE: 20220429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROSENWALD LINDSAY A MD CENTRAL INDEX KEY: 0000941841 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35366 FILM NUMBER: 22875897 MAIL ADDRESS: STREET 1: 375 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10152 FORMER NAME: FORMER CONFORMED NAME: ROSENWALD LINDSAY MD DATE OF NAME CHANGE: 19950316 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fortress Biotech, Inc. CENTRAL INDEX KEY: 0001429260 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205157386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 FORMER COMPANY: FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC DATE OF NAME CHANGE: 20080310 4 1 tm2213913-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-01 0 0001429260 Fortress Biotech, Inc. FBIO 0000941841 ROSENWALD LINDSAY A MD C/O FORTRESS BIOTECH, INC. 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLAND FL 33154 1 1 1 0 PRESIDENT, CEO & CHAIRMAN COMMON STOCK, PAR VALUE $0.001 2021-06-01 4 A 0 1297 2.31 A 10408336 D COMMON STOCK, PAR VALUE $0.001 2021-09-30 4 J 0 8133 0 A 10416469 D COMMON STOCK, PAR VALUE $0.001 2021-11-16 4 J 0 4619 0 A 10421088 D COMMON STOCK, PAR VALUE $0.001 2021-12-01 4 A 0 1250 2.42 A 10422338 D COMMON STOCK, PAR VALUE $0.001 2022-01-01 4 A 0 1102986 0 A 11525324 D Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock. The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock. The reporting person was granted 1,102,986 restricted shares pursuant to the issuer's Long-Term Incentive Plan on January 1, 2022. /s/ Samuel Berry, Attorney-in-Fact 2022-04-29